CA2345273A1 - Pharmaceutically active compounds and methods of use thereof - Google Patents

Pharmaceutically active compounds and methods of use thereof Download PDF

Info

Publication number
CA2345273A1
CA2345273A1 CA002345273A CA2345273A CA2345273A1 CA 2345273 A1 CA2345273 A1 CA 2345273A1 CA 002345273 A CA002345273 A CA 002345273A CA 2345273 A CA2345273 A CA 2345273A CA 2345273 A1 CA2345273 A1 CA 2345273A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
mammal
integer
alkylsulfinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345273A
Other languages
English (en)
French (fr)
Inventor
Jin-An Jiao
Lawrence K. Luepschen
Esperanza L. Nieves
Hing C. Wong
Dean P. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345273A1 publication Critical patent/CA2345273A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/386—Polyphosphonic acids containing hydroxy substituents in the hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002345273A 1998-09-25 1999-09-24 Pharmaceutically active compounds and methods of use thereof Abandoned CA2345273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10188798P 1998-09-25 1998-09-25
US60/101,887 1998-09-25
PCT/US1999/022238 WO2000018398A1 (en) 1998-09-25 1999-09-24 Pharmaceutically active compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2345273A1 true CA2345273A1 (en) 2000-04-06

Family

ID=22286985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345273A Abandoned CA2345273A1 (en) 1998-09-25 1999-09-24 Pharmaceutically active compounds and methods of use thereof

Country Status (7)

Country Link
US (3) US6828312B2 (enExample)
EP (1) EP1115396A4 (enExample)
JP (1) JP2002525323A (enExample)
AU (1) AU769647B2 (enExample)
CA (1) CA2345273A1 (enExample)
TW (1) TWI222865B (enExample)
WO (1) WO2000018398A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
WO2000018398A1 (en) * 1998-09-25 2000-04-06 Sunol Molecular Corporation Pharmaceutically active compounds and methods of use thereof
EP1829535A3 (en) * 1999-10-27 2007-10-24 Tanox, Inc. Tissue factor antagonists and methods of use thereof
KR20070049251A (ko) 1999-10-27 2007-05-10 타녹스 인코퍼레이티드 조직 인자 길항제 및 그의 사용 방법
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
CN1863556B (zh) * 2003-06-19 2012-05-16 吉宁特有限公司 用于治疗凝血相关紊乱的组合物和方法
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2005123856A1 (ja) 2004-06-17 2005-12-29 Sharp Kabushiki Kaisha 塗液、膜の製造方法、機能素子の製造方法、及び、機能素子
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP2386861A3 (en) 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
CA2615078A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Methods for determining the effect of a treatment on the cross-.beta. structure content of a protein; selection of treatments and uses thereof
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
WO2007108675A1 (en) * 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
EP2667444A1 (en) 2012-05-21 2013-11-27 Solvay Sa Use of fluorinated 2-methoxymalonic acid esters in electrolyte or solvent compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379146A (en) * 1981-02-17 1983-04-05 Merck & Co., Inc. Substituted phosphonamides as antihypertensives
DE3203307A1 (de) 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Phosphonate, und diese enthaltende pharmazeutische verbindungen
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
DE3736113A1 (de) * 1987-10-26 1989-05-03 Hoechst Ag Arzneimittel, darin enthaltene phosphorhaltige 2-isoxazoline und isoxazole, sowie herstellungsverfahren fuer diese heterocyclischen verbindungen
IT1241674B (it) 1989-10-12 1994-01-27 Boehringer Biochemia Srl Acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono.
JPH05148277A (ja) 1991-11-05 1993-06-15 Banyu Pharmaceut Co Ltd アミノホスホン酸誘導体
WO1994007501A1 (en) 1992-09-23 1994-04-14 The Upjohn Company Arylmethylphosphonates and phosphonic acids useful as anti-inflammatory agents
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5728650A (en) 1993-10-07 1998-03-17 Zeneca Limited Herbicidal aza bisphosphonic acids and compositions containing the same
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
US6096730A (en) * 1997-07-24 2000-08-01 University Of Kentucky Research Foundation Phosphonated agents and their antiangiogenic and antitumorigenic use
DE19738005A1 (de) 1997-08-30 1999-03-04 Bayer Ag Verwendung von substituierten 1,1-Bisphosphonaten
WO2000018398A1 (en) 1998-09-25 2000-04-06 Sunol Molecular Corporation Pharmaceutically active compounds and methods of use thereof
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists

Also Published As

Publication number Publication date
US20020065327A1 (en) 2002-05-30
US6828312B2 (en) 2004-12-07
JP2002525323A (ja) 2002-08-13
US20070155703A1 (en) 2007-07-05
US7199113B2 (en) 2007-04-03
AU6264699A (en) 2000-04-17
US20050245488A1 (en) 2005-11-03
EP1115396A4 (en) 2002-05-22
WO2000018398A1 (en) 2000-04-06
EP1115396A1 (en) 2001-07-18
TWI222865B (en) 2004-11-01
AU769647B2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
US20070155703A1 (en) Pharmaceutically active compounds and methods of use thereof
AU784426C (en) Tissue factor antagonists and methods of use thereof
US6238878B1 (en) FVlla/TF activity inhibiting compounds
Chen et al. Anti-thrombotic effects mediated by dihydromyricetin involve both platelet inhibition and endothelial protection
JP2022513919A (ja) 血栓性または血小板塞栓性疾患および／または血栓性または血小板塞栓性合併症の治療および／または予防のための置換オキソピリジン誘導体
Prasa et al. Inhibition of thrombin generation in plasma by inhibitors of factor Xa
Furugohri et al. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin
US4954519A (en) Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
ZA200104770B (en) Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor XA activity).
US5859010A (en) Factor VII -binding reagent
EP1882695A2 (en) Pharmaceutically active compounds and methods of use thereof
Hasan et al. Thrombostatin inhibits induced canine coronary thrombosis
EP1829535A2 (en) Tissue factor antagonists and methods of use thereof
Kawamura et al. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: Possible role of PAF in tissue factor generation
AU2006200377A1 (en) Tissue factor antagonists and methods of use thereof
US5559150A (en) N,N-disulfonylated aminobenzene carboxlic acids and the use thereof as thrombin inhibitors
KR20030007937A (ko) 멜라가트란 및 ＶＩＩａ 인자 억제제를 포함하는 조합물
AU2001264495A1 (en) A combination product comprising melagatran and a factor VIIa inhibitor
Callas et al. Studies on the thrombogenic effects of recombinant tissue factor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued